09 June 2021 | Wednesday | News
Essent Biologics Launches Human Mesenchymal Stem Cells For Regenerative Medicine, Biopharmaceutical And Cell Therapy Research
Essent Biologics will provide highly-characterized, low-passaged hMSCs. Each vial will contain over one million cells at thaw and have a passage level of P0 or P1 to ensure potency.
The company's hMSCs are the first commercial hMSC product that is recovered, expanded and cryopreserved without the use of antibiotics or animal products. Additionally, with each order of hMSCs, Essent Biologics can provide full donor information coupled with a source biopsy called the Essent Origin Sample™.
"This is an important milestone in getting our products into the hands of brilliant researchers," said Corey Stone, Executive Director, Essent Biologics. "Our stem cells are the ideal input to your experiment, whether you are developing cell-based therapies, spheroids, bioprinted constructs, microfluidic chips or complex in vitro models."
As a strategic venture from AlloSource, a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients, Essent Biologics' hMSCs are produced under current Good Manufacturing Practices (cGMP). The company builds their hMSCs to align with International Society for Cell & Gene Therapy (ISCT) guidelines to ensure identity, function and sterility.